Terlipressin Given As I.V. Boluses Versus Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal Syndrome

Last updated: October 11, 2014
Sponsor: University of Padova
Overall Status: Trial Status Unknown

Phase

2/3

Condition

Hepatic Fibrosis

Liver Failure

Liver Disorders

Treatment

N/A

Clinical Study ID

NCT00742690
1442P
  • Ages 18-75
  • All Genders

Study Summary

It is well known that terlipressin and albumin improve renal function in patients with cirrhosis and type 1 HRS. In previous studies terlipressin has been used either as intravenous boluses moving from an initial dose of 0.5-1 mg/4 hr or as continuous intravenous infusion at the initial dose of 2 mg/24 h. Up to now the two schedules of i.v. administration of terlipressin have never been compared. Nevertheless, it has been hypothesized that continuous intravenous infusion assures a more steady profile of effect on portal pressure in patients with cirrhosis. Thus, the aim of the study will be to compare terlipressin given as i.v. bolus vs terlipressin given as continuous intravenous infusion in the treatment of type 1 HRS in patients with cirrhosis.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients with cirrhosis and type 1 HRS

Exclusion

Exclusion Criteria:

  • HCC beyond the Milan Criteria,septic shock (systolic arterial pressure < 90 mmHg,

  • Significant heart or respiratory failure,

  • Peripheral arteriophaty clinically significant,

  • Previous heart stroke or significant alteration of the ECG

Study Design

Total Participants: 70
Study Start date:
May 01, 2005
Estimated Completion Date:
March 31, 2015

Connect with a study center

  • Liver Unit, General Hospital

    Padova, 35100
    Italy

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.